A sincere hat tip to Ed Silverman, here -- this new report is chock full of illuminating tidbits, and Ed covers quite a few of them, at Pharmalot, this morning. The survey Quintiles conducted polled 144 biopharma executives and 129 managed care executives (thus the law of small numbers may apply, here).
In any event, I was particularly struck by the graphic at right (which I've taken the liberty to reformat for clarity and design sense) -- click to enlarge. Nearly half of both the payors (managed care organizations) -- and the biopharma companies, themselves -- feel biopharma needs to do a better job of demonstrating its collective value, in the health care marketplace.
That's truly remarkable. I'll have more, soon -- but here is how Quintiles asked the question:
. . . .What should be the most important priority for biopharmaceutical companies as the industry continues to change?
[And, from the report's intro]. . . .In the new health [regime], declining R&D productivity combined with increased development costs have made investment portfolio managers skittish. The risks associated with drug development are extremely high, and the lack of output ahead of the patent cliff is worrisome to industry insiders and observers. To manage this new high-risk environment -- and continue to deliver valuable and accessible therapies -- biopharma companies must find ways to increase output, decrease costs and restructure legacy systems and infrastructures that hinder innovation. The New Health Report reveals disparities between biopharma and managed care executives about the concept of biopharma companies working together. . . .
More soon.
No comments:
Post a Comment